Prelude Therapeutics Inc Financials
Prelude Therapeutics Inc (PRLD) reported $12.1M in revenue for fiscal year 2025, up 73.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Prelude’s economics are driven by research spending, with liquidity increasingly supported by financing rather than revenue.
FY2025 looked better because cash rose to$35.3M while operating cash burn narrowed to-$56.3M . But the cash rebuild came from investment inflows and financing rather than operations, leaving near-term liquidity improved but leverage heavier as liabilities reached$72.7M and debt-to-equity moved to 1.1x.
The narrower FY2025 loss came mainly from spending restraint, not commercial scale: R&D fell to
This is a capital-light burn model: capital spending was just
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Prelude Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Prelude Therapeutics Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 19/100.
Prelude Therapeutics Inc's revenue surged 73.4% year-over-year to $12.1M, reflecting rapid business expansion. This strong growth earns a score of 97/100.
Prelude Therapeutics Inc has a moderate D/E ratio of 1.06. This balance of debt and equity financing earns a leverage score of 45/100.
Prelude Therapeutics Inc's current ratio of 1.99 indicates adequate short-term liquidity, earning a score of 57/100. The company can meet its near-term obligations, though with limited headroom.
Prelude Therapeutics Inc's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.
Prelude Therapeutics Inc posts a -145.0% return on equity (ROE), meaning it loses $145 for every $100 of shareholders' equity. This results in a returns score of 30/100. This is down from -96.7% the prior year.
Prelude Therapeutics Inc scores -4.39, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($518.7M) relative to total liabilities ($72.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Prelude Therapeutics Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Prelude Therapeutics Inc reported a net loss of $99.5M while operations used $56.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Prelude Therapeutics Inc generated $12.1M in revenue in fiscal year 2025. This represents an increase of 73.4% from the prior year.
Prelude Therapeutics Inc's EBITDA was -$102.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.4% from the prior year.
Prelude Therapeutics Inc reported -$99.5M in net income in fiscal year 2025. This represents an increase of 21.8% from the prior year.
Prelude Therapeutics Inc earned -$1.29 per diluted share (EPS) in fiscal year 2025. This represents an increase of 23.2% from the prior year.
Cash & Balance Sheet
Prelude Therapeutics Inc recorded an outflow of $56.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 45.6% from the prior year.
Prelude Therapeutics Inc held $35.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Prelude Therapeutics Inc's ROE was -145.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 48.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Prelude Therapeutics Inc invested $94.3M in research and development in fiscal year 2025. This represents a decrease of 20.1% from the prior year.
Prelude Therapeutics Inc invested $67K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 91.2% from the prior year.
Not reported for fiscal year 2025.
PRLD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $12.1M+73.4% | $7.0M | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $94.3M-20.1% | $118.0M+14.1% | $103.4M+11.3% | $92.9M+7.0% | $86.8M+80.1% | $48.2M+98.4% | $24.3M |
| SG&A Expenses | N/A | $22.4M-22.0% | $28.7M-0.6% | $28.9M-5.8% | $30.7M+13.7% | $27.0M+154.6% | $10.6M+176.4% | $3.8M |
| Operating Income | N/A | -$104.6M+25.2% | -$139.7M-5.6% | -$132.3M-7.1% | -$123.5M-8.6% | -$113.7M-93.5% | -$58.8M-109.1% | -$28.1M |
| Income Tax | N/A | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$99.5M+21.8% | -$127.2M-4.4% | -$121.8M-5.5% | -$115.4M-3.4% | -$111.7M-96.2% | -$56.9M-106.5% | -$27.6M |
| EPS (Diluted) | — | -$1.29+23.2% | -$1.68+16.8% | -$2.02+17.2% | -$2.44-0.4% | -$2.43 | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PRLD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $141.3M-19.5% | $175.5M-36.8% | $277.7M+25.9% | $220.5M-27.7% | $305.1M+36.5% | $223.6M+922.3% | $21.9M |
| Current Assets | $105.7M-22.2% | $135.9M-42.3% | $235.6M+15.3% | $204.4M-30.7% | $295.1M+33.7% | $220.8M+991.8% | $20.2M |
| Cash & Equivalents | $35.3M+182.6% | $12.5M-50.7% | $25.3M-17.4% | $30.6M-3.8% | $31.8M-85.4% | $218.3M+1056.4% | $18.9M |
| Total Liabilities | $72.7M+65.0% | $44.1M+8.6% | $40.6M+61.9% | $25.1M+30.5% | $19.2M+68.3% | $11.4M-84.0% | $71.3M |
| Current Liabilities | $53.0M+106.7% | $25.6M+17.5% | $21.8M+0.6% | $21.7M+13.0% | $19.2M+68.8% | $11.4M+135.3% | $4.8M |
| Total Equity | $68.6M-47.8% | $131.5M-44.6% | $237.1M+21.3% | $195.4M-31.6% | $285.9M+34.7% | $212.2M+529.4% | -$49.4M |
| Retained Earnings | -$683.1M-17.1% | -$583.6M-27.9% | -$456.4M-36.4% | -$334.6M-52.7% | -$219.1M-104.0% | -$107.4M-112.7% | -$50.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PRLD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$33.3M | -$56.3M+45.3% | -$102.9M+3.9% | -$107.1M-27.9% | -$83.7M-0.2% | -$83.5M-80.9% | -$46.2M-79.9% | -$25.7M |
| Capital Expenditures | $0 | $67K-91.2% | $764K-78.3% | $3.5M+16.4% | $3.0M+30.0% | $2.3M+274.1% | $621K-20.4% | $780K |
| Free Cash Flow | -$33.3M | -$56.4M+45.6% | -$103.7M+6.3% | -$110.6M-27.5% | -$86.7M-1.0% | -$85.9M-83.5% | -$46.8M-77.0% | -$26.4M |
| Investing Cash Flow | -$77.3M | $53.5M-40.7% | $90.2M+360.3% | -$34.6M-142.4% | $81.7M+131.0% | -$263.8M-42380.4% | -$621K+20.4% | -$780K |
| Financing Cash Flow | $110.4M | $24.8M+20780.0% | -$120K-100.1% | $136.4M+16635.6% | $815K-99.5% | $164.9M-33.0% | $246.2M+728.2% | $29.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PRLD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -861.3% | -1995.9% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -819.6% | -1816.7% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -145.0%-48.2pp | -96.7%-45.4pp | -51.4%+7.7pp | -59.1%-20.0pp | -39.1%-12.2pp | -26.8% | N/A |
| Return on Assets | -70.4%+2.1pp | -72.5%-28.6pp | -43.9%+8.5pp | -52.3%-15.7pp | -36.6%-11.1pp | -25.5%+100.6pp | -126.1% |
| Current Ratio | 1.99-3.3x | 5.30-5.5x | 10.79+1.4x | 9.42-6.0x | 15.37-4.0x | 19.41+15.2x | 4.18 |
| Debt-to-Equity | 1.06+0.7x | 0.34+0.2x | 0.170.0x | 0.13+0.1x | 0.070.0x | 0.05 | N/A |
| FCF Margin | -464.3% | -1480.7% | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Prelude Therapeutics Inc Ranks
Frequently Asked Questions
What is Prelude Therapeutics Inc's annual revenue?
Prelude Therapeutics Inc (PRLD) reported $12.1M in total revenue for fiscal year 2025. This represents a 73.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Prelude Therapeutics Inc's revenue growing?
Prelude Therapeutics Inc (PRLD) revenue grew by 73.4% year-over-year, from $7.0M to $12.1M in fiscal year 2025.
Is Prelude Therapeutics Inc profitable?
No, Prelude Therapeutics Inc (PRLD) reported a net income of -$99.5M in fiscal year 2025.
What is Prelude Therapeutics Inc's EBITDA?
Prelude Therapeutics Inc (PRLD) had EBITDA of -$102.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Prelude Therapeutics Inc's return on equity (ROE)?
Prelude Therapeutics Inc (PRLD) has a return on equity of -145.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Prelude Therapeutics Inc's free cash flow?
Prelude Therapeutics Inc (PRLD) recorded an outflow of $56.4M in free cash flow during fiscal year 2025. This represents a 45.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Prelude Therapeutics Inc's operating cash flow?
Prelude Therapeutics Inc (PRLD) recorded an outflow of $56.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Prelude Therapeutics Inc's total assets?
Prelude Therapeutics Inc (PRLD) had $141.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Prelude Therapeutics Inc's capital expenditures?
Prelude Therapeutics Inc (PRLD) invested $67K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Prelude Therapeutics Inc spend on research and development?
Prelude Therapeutics Inc (PRLD) invested $94.3M in research and development during fiscal year 2025.
What is Prelude Therapeutics Inc's current ratio?
Prelude Therapeutics Inc (PRLD) had a current ratio of 1.99 as of fiscal year 2025, which is generally considered healthy.
What is Prelude Therapeutics Inc's debt-to-equity ratio?
Prelude Therapeutics Inc (PRLD) had a debt-to-equity ratio of 1.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Prelude Therapeutics Inc's return on assets (ROA)?
Prelude Therapeutics Inc (PRLD) had a return on assets of -70.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Prelude Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Prelude Therapeutics Inc (PRLD) had $35.3M in cash against an annual operating cash burn of $56.3M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Prelude Therapeutics Inc's Altman Z-Score?
Prelude Therapeutics Inc (PRLD) has an Altman Z-Score of -4.39, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Prelude Therapeutics Inc's Piotroski F-Score?
Prelude Therapeutics Inc (PRLD) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Prelude Therapeutics Inc's earnings high quality?
Prelude Therapeutics Inc (PRLD) reported a net loss of $99.5M while operations used $56.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Prelude Therapeutics Inc?
Prelude Therapeutics Inc (PRLD) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.